ArticleJournal of pain research2026
A Single-Day Intravenous Ketamine Infusions for Fibromyalgia, a Large Retrospective Study with a Long-Term Assessment.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Fibromyalgia is a complex chronic neurosensory disorder that affects approximately 2% of the population. Ketamine acts as a non-competitive antagonist of the N-methyl-D-aspartate receptor, which plays a crucial role in nociceptive hypersensitivity. Small studies, case reports and several randomized studies demonstrated substantial reductions in pain. However, these studies enrolled few participants (between 11 and 34), and did not report on repeated infusions over prolonged periods of time. Here, we describe a large real-world retrospective assessment of repeated IV ketamine infusions for severe fibromyalgia pain. Methods: A total of 92 consecutive patients were treated with repeated single-day intravenous (IV) ketamine infusions for fibromyalgia. Outcome data were collected and analyzed. Patients received approximately 1.5 mg/kg/hour of ketamine during a 3-hour infusion session, repeated as needed every 3-10 months (median interval of 6 months). Data were summarized using descriptive statistics for continuous variables. Results: Ninety-two female patients, aged 24-78 years (median age 49 years) with median BMI of 32.4, received repeated ketamine infusions for the management of fibromyalgia pain. Thirty-three of the 92 patients were receiving opioids at baseline, with a median morphine sulfate equivalent (MSO4) dose of 30 mg daily. Patients received between 1 and 32 infusions, averaging one infusion every 6 months. The median baseline pain score was 8, which decreased to 5 at the 3-month follow-up and remained stable at 5 through 24 months. At 3 months, 32 of 92 patients reported greater than 50% pain relief, and 30 of 92 at 24 months. Nineteen patients reported minimal or no benefit from treatment. The number of patients receiving opioids decreased from 33 at baseline to 27 at 24-month. Conclusion: Ketamine infusions provided substantial and sustained pain relief in the majority of patients with fibromyalgia. Repeated ketamine infusions were associated with consistent pain reduction over a 24-month period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.